telbivudine/LDT600
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Compensated Chronic Hepatitis B
Conditions
Compensated Chronic Hepatitis B
Trial Timeline
Mar 1, 2009 → —
NCT ID
NCT00877149About telbivudine/LDT600
telbivudine/LDT600 is a approved stage product being developed by Novartis for Compensated Chronic Hepatitis B. The current trial status is completed. This product is registered under clinical trial identifier NCT00877149. Target conditions include Compensated Chronic Hepatitis B.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00877149 | Approved | Completed |
Competing Products
9 competing products in Compensated Chronic Hepatitis B
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| Mesenchymal Stem Cell | Rohto Pharmaceutical | Pre-clinical | 23 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1/2 | 41 |
| Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV | Merck | Approved | 85 |
| Terlipressin acetate + Serelaxin (RLX030) | Novartis | Phase 2 | 52 |
| Aliskiren + Placebo | Novartis | Phase 3 | 77 |
| Telbivudine/LDT600A | Novartis | Approved | 85 |
| BMS-986259 | Bristol Myers Squibb | Phase 2 | 51 |
| Albutein 20% | Grifols | Phase 3 | 74 |